• 13.15-13.45: A. Klein: Natural history MDC1A
• 13.45-14.15: R. de Coo: Mild and atypical MDC1A
• 14:15-14.45: H. Topaloglu: Clinical experience MDC1A
• 14.45-15.10: D-J. and H. Stelwagen: The patient perspective
• 15.10-15.35: M. Beare: The parent perspective (USA)
• 15.35-16.05: A. Sarkozy: Congenital muscle disease
• 16.05-16.15: Discussion, wrap-up and conclusions

• 16.30-17.00: G. Dziewczapolski: Clinical-Trial Readiness for LAMA2 disease
• 17.00-17.30: N. Voermans/C. Erasmus: Towards Trial Readiness
• 17.30-18.00: M. Durbeej: Compound-based therapy
• 18.00-18.30: H. Sawnani: Preserving pulmonary function

• 08.30-09.00: R. Foley: Clinical trials for MDC1A
• 09.00-09.30: M. Girgenrath: Combinatorial therapy
• 09.30-10.00: D. Kemaladewi: Genetic correction LAMA2 mutation in mouse model
• 10.00-10.30: Discussion

Open to all registrants. The complete programme can be found here.

• 08.30-09.00: P. Yurchenco: LAMA2 Linker Protein repair
• 09.00-09.30: M. Rüegg: Protein replacement therapy MDC1A
• 09.30-10.00: M. Sampaolesi: Mesoangioblast-therapy in animal models of muscular dystrophy
• 10.00-10.30: S. Previtali: Mesoangioblast-therapy in a MDC1A mouse model

• 11.00-11.30: F. Van Tienen: Muscle stem-cell in humans
• 11.30-12.00: G. Cossu: Mesoangioblast-based therapy DMD
• 12.00-13.00: H. smeets/B. Verbrugge: Discussion, wrap-up and conclusions